• Internal medicine · Jul 2024

    Case Reports

    Development of Remitting Seronegative Symmetrical Synovitis with Pitting Edema Syndrome with Pembrolizumab for Lung Squamous Cell Carcinoma: A Case Report.

    • Misaki Yoshida, Satoshi Hara, Ryo Nishioka, Takafumi Kobayashi, Yuya Murase, Hideharu Kimura, Ichiro Mizushima, and Mitsuhiro Kawano.
    • Department of Rheumatology, Kanazawa University Hospital, Japan.
    • Intern. Med. 2024 Jul 15; 63 (14): 208920962089-2096.

    AbstractImmune checkpoint inhibitors (ICIs) can cause immune-related adverse events (irAEs). There are a few case reports of remitting seronegative symmetrical synovitis with pitting edema syndrome (RS3PE) as an irAE. We herein report a 49-year-old Japanese man who developed acute-onset polyarthralgia and edema of the back of both hands and bilateral lower legs after pembrolizumab administration for lung cancer. The patient's lung cancer was in complete remission, leading to the diagnosis of RS3PE induced by pembrolizumab rather than malignancy. When patients show RS3PE during ICI treatment, rheumatologists should consider the possibility of an irAE after excluding malignancy and systemic diseases.

      Pubmed     Copy Citation     Plaintext  

      Add institutional full text...

    Notes

     
    Knowledge, pearl, summary or comment to share?
    300 characters remaining
    help        

    hide…